Learn about Stop Loss industry claim trends, including the impact of gene and cell therapies, and how they are affecting claim costs for self-funded employers.
Biologics are one of the fastest growing category of drugs—and one of the most expensive—making it challenging to balance cost with safety and efficacy. And it's even more challenging to incorporate unbranded biologics and biosimilars into benefits plans.
The American Cancer Society announced changes to its lung cancer screening guidelines, expanding their recommendations to all people over 50 who smoked more than 20 packs per year, and removing the minimum requirement for 'years since quitting.'
In the US, total healthcare spending related to cancer is projected to reach $246 billion by 2030– a 34% increase since 2015. With nearly 50% of the population receiving healthcare insurance through their employer, the lion's share of the cost increase has fallen on employers' shoulders.
In this webinar, we speak with benefit experts from leading employers and advisories to better understand why the conversation around menopause at work is starting to take place at a higher volume.
Learn what your peers are thinking and doing in this now business-critical area, but also how your organization can better select and implement digital health options.
Many employers are offering robust benefits packages to their employees – including preventative health solutions – but are those offerings being utilized to the fullest extent possible? Gain not only valuable insight on what your peers are doing and thinking but to hear a real-world benefits success story.
